|
Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER. |
|
|
Leadership - Infinity Pharmaceuticals; Varian Medical Systems |
Stock and Other Ownership Interests - GRAIL; Infinity Pharmaceuticals; Juno Therapeutics; PMV Pharma; Varian Medical Systems |
Consulting or Advisory Role - GRAIL; Lilly; Novartis |
|
|
Honoraria - amgen; Eisai; Roche |
Consulting or Advisory Role - Roche |
Travel, Accommodations, Expenses - AstraZeneca; Roche Canada |
|
|
Stock and Other Ownership Interests - MedSIR |
Honoraria - Celgene; Eisai; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Biothera; Celgene; Cellestia Biotech; Merus; Roche |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; Lilly; Novartis; Pfizer; Roche/Genentech |
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - AstraZeneca; Novartis; Pfizer; Roche |
|
|
Honoraria - Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Celgene; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche/Genentech; Sandoz |
Research Funding - Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
|
|
Consulting or Advisory Role - Genentech/Roche; Macrogenics |
Research Funding - Genentech/Roche |
|
|
Leadership - Oncology Education |
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Merck; Novartis; Pfizer; Roche/Genentech |
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Novartis; Pfizer; Roche/Genentech; Spectrum Pharmaceuticals |
|
|
|
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Genentech |
|
|
|
Stock and Other Ownership Interests - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
|
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Genentech |
Travel, Accommodations, Expenses - Genentech |
|
|
Honoraria - AstraZeneca; Celgene; Eisai; Novartis; Pfizer; Roche |
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; Roche |
Research Funding - AstraZeneca; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Pfizer; Roche |
Research Funding - AstraZeneca (Inst) |